MY208231A - Mavacamten for use in the treatment of hypertrophic cardiomyopathy - Google Patents

Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Info

Publication number
MY208231A
MY208231A MYPI2020000493A MYPI2020000493A MY208231A MY 208231 A MY208231 A MY 208231A MY PI2020000493 A MYPI2020000493 A MY PI2020000493A MY PI2020000493 A MYPI2020000493 A MY PI2020000493A MY 208231 A MY208231 A MY 208231A
Authority
MY
Malaysia
Prior art keywords
mavacamten
treatment
hypertrophic cardiomyopathy
cardiomyopathy
hypertrophic
Prior art date
Application number
MYPI2020000493A
Other languages
English (en)
Inventor
Marc J Semigran
June H Lee
Joseph Lambing
Eric Green
Marc Evanchik
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of MY208231A publication Critical patent/MY208231A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
MYPI2020000493A 2017-08-04 2018-08-03 Mavacamten for use in the treatment of hypertrophic cardiomyopathy MY208231A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US201862671585P 2018-05-15 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Publications (1)

Publication Number Publication Date
MY208231A true MY208231A (en) 2025-04-25

Family

ID=63350605

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020000493A MY208231A (en) 2017-08-04 2018-08-03 Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Country Status (17)

Country Link
US (5) US20200054636A1 (enExample)
EP (2) EP3661514B1 (enExample)
JP (3) JP2020529996A (enExample)
KR (2) KR20250116181A (enExample)
CN (2) CN111182901A (enExample)
AU (2) AU2018311974B2 (enExample)
CA (1) CA3071948A1 (enExample)
IL (2) IL322175A (enExample)
LT (1) LT3661514T (enExample)
MA (1) MA49760A (enExample)
MX (3) MX2020001406A (enExample)
MY (1) MY208231A (enExample)
RU (1) RU2020109345A (enExample)
SG (2) SG10202112960QA (enExample)
SM (1) SMT202500413T1 (enExample)
UY (1) UY37834A (enExample)
WO (1) WO2019028360A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI835770B (zh) 2018-01-19 2024-03-21 美商胞質動力學公司 心肌節抑制劑
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
TW202134259A (zh) * 2019-11-10 2021-09-16 美商邁奧卡迪亞公司 用肌凝蛋白調節劑之治療方法
CA3165995A1 (en) * 2020-01-28 2021-08-05 Lorena KORDIC Solid state forms of mavacamten and process for preparation thereof
CA3190060A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
TW202227420A (zh) 2020-11-20 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 三嗪二酮類衍生物、其製備方法及其在醫藥上的應用
US20240082248A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
EP4301760A1 (en) 2021-03-04 2024-01-10 Cytokinetics, Inc. Cardiac sarcomere inhibitors
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
PL4370116T3 (pl) * 2021-07-16 2025-04-28 Cytokinetics, Inc. Schematy dawkowania afikamtenu do leczenia obturacyjnej kardiomiopatii przerostowej
EP4404846B1 (en) * 2021-09-24 2025-10-08 Koninklijke Philips N.V. Methods and systems for generating likelihood of heart failure with preserved ejection fraction (hfpef)
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache

Also Published As

Publication number Publication date
CN111182901A (zh) 2020-05-19
SG10202112960QA (en) 2021-12-30
US20240423981A1 (en) 2024-12-26
IL272300B1 (en) 2025-08-01
TW201916882A (zh) 2019-05-01
MX2024000348A (es) 2024-01-26
LT3661514T (lt) 2025-11-10
AU2018311974B2 (en) 2024-03-07
SMT202500413T1 (it) 2025-11-10
US20220226324A1 (en) 2022-07-21
IL322175A (en) 2025-09-01
JP2020529996A (ja) 2020-10-15
US20220313695A1 (en) 2022-10-06
AU2024203872A1 (en) 2024-06-27
JP2025020292A (ja) 2025-02-12
SG11202000549TA (en) 2020-02-27
KR20250116181A (ko) 2025-07-31
EP3661514A1 (en) 2020-06-10
AU2018311974A1 (en) 2020-02-06
IL272300A (en) 2020-03-31
CN118593507A (zh) 2024-09-06
MA49760A (fr) 2020-06-10
MX2024008096A (es) 2024-07-15
CA3071948A1 (en) 2019-02-07
US20250213565A1 (en) 2025-07-03
WO2019028360A1 (en) 2019-02-07
EP4659806A2 (en) 2025-12-10
MX2020001406A (es) 2020-03-09
JP2023065372A (ja) 2023-05-12
UY37834A (es) 2019-02-28
EP3661514B1 (en) 2025-09-17
KR20200035973A (ko) 2020-04-06
US20200054636A1 (en) 2020-02-20
RU2020109345A (ru) 2021-09-06

Similar Documents

Publication Publication Date Title
MY208231A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
CA193736S (en) Skin massager
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2017010150A (es) Bacterias probioticas recombinantes.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
PH12019501373A1 (en) Methods of treating cochlears synaptopathy
MY190411A (en) Improved uricase sequences and methods of treatment
IL271728A (en) Materials, uses and treatment methods
HK1258276A1 (zh) 用於治疗hiv的化合物和组合
MX2017000306A (es) Metodos para tratar hipotension.
MX2020008195A (es) Compuestos para el tratamiento del dolor.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
ZA202211980B (en) Methods and treatment of trauma
PH12017500275A1 (en) Methods of treating depression using nmda modulators
MX2020004058A (es) Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.
MX2017013047A (es) Tratamiento de dolor.
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
PH12016501838A1 (en) Compounds and their methods of use
MX2020003587A (es) Metodo de tratamiento de una lamina de metal y la lamina de metal tratada con este metodo.
MX2020003633A (es) Metodo de tratamiento de una lamina de metal y la lamina de metal tratada con este metodo.
MY200803A (en) Mpo inhibitors for use in medicine
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.